Fragment 176-191
low riskAlso: HGH Fragment 176-191 · HGH Frag · Fat loss peptide
Fragment 176-191 is a C-terminal HGH fragment associated with fat metabolism. Related to AOD-9604. Animal studies show selective lipolytic effects. Human clinical data is very limited — primarily animal and anecdotal. Heavily marketed but evidence is thin.
Reported Benefits
Lipolysis / fat reduction
Animal models show selective fat reduction. Human data essentially anecdotal.
Mechanism of Action
Selectively activates lipolysis without affecting IGF-1 or insulin sensitivity via C-terminal HGH mechanism.
AOD-9604 vs. Fragment 176-191
Closely related compounds — AOD-9604 is the modified/stabilized version. AOD-9604 at least has Phase III trial data (even though it failed). Fragment 176-191 human data is essentially absent beyond Phase I safety.
Evidence claims circulating online significantly exceed what the actual research supports.
✦ Sponsored
Stop Guessing About Your Health. Start Optimizing It.
Advanced diagnostics and licensed medical providers delivering personalized longevity care to uncover root causes, optimize health, and track progress virtually or in person.
Learn More →
Regulatory Status
Research OnlySafety Profile
Side Effects
- •Mild injection site reactions
- •Possible mild hypoglycemia
Contraindications
- •Pregnancy
Primary Uses
Related Peptides
Planning a protocol?
Use the AI Stack Builder to generate a phased schedule, compatibility analysis, and monitoring checklist.
Weekly Briefing
Regulatory updates + new study breakdowns.
For Practitioners
Do you prescribe Fragment 176-191?
Get in front of patients who've already researched this protocol and are ready to consult. Featured listings from $199/mo.
Get Listed →